Sera Prognostics raises $36M to market its blood test that predicts risk of premature birth

NICU
Sera’s blood test assesses preterm birth risk as early as 19 weeks to allow for earlier interventions to prolong gestation and help improve the health of the baby. (Pixelistanbul/Getty)

Sera Prognostics, maker of a prenatal blood test to help predict the risk of premature births, has raised $36 million in venture capital funding to help commercialize its offering.

The Salt Lake City-based company’s series D round was led by Blue Ox Healthcare Partners, with additional, returning investments from diagnostic testing giant LabCorp, as well as Domain Associates, InterWest Partners, Catalyst Health Ventures and Chione.

“Preterm birth—the leading cause of infant mortality—is an unaddressed global crisis, accounting for over $30 billion in excess annual spending in the U.S. alone,” Sera’s chairman and CEO, Gregory Critchfield, M.D., said in a statement. The round’s proceeds will also help fund work in gauging the test’s real-world impacts, both clinically and economically.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Sera’s PreTRM test uses blood-based biomarkers to assess a pregnant woman’s risk of spontaneous, preterm birth involving a single child at as early as 19 weeks, including in women who may not have other symptoms.

RELATED: Sera Prognostics taps industry niche with preterm birth risk test

This can allow for earlier interventions designed to prolong gestation and help improve the health of the baby, according to the company.

“As a result, we believe PreTRM will be the go-to solution for commercial plans, Medicaid programs, employers and risk-based providers seeking to effectively manage the clinical and economic epidemic of preterm birth,” said Blue Ox Managing Partner Charles Kennedy, M.D.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.